Tessera Therapeutics

Gene editing
#Advanced Therapies #Fast Track designation #FDA #Gene editing #Gene therapy #Tessera Therapeutics

In vivo gene editing programme for AATD fast-tracked by FDA

The US Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to TSRA-196, Tessera Therapeutics’ lead in vivo gene editing programme.  TSRA-196 is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD) who are homozygous for the PiZ allele (PiZZ).  … Read More

#Editor's Choice #News #Regulatory

#Bill & Melinda Gates Foundation #Funding #Genetic medicines #Sickle cell disorder (SCD) #Tessera Therapeutics

Investment to develop in vivo genetic treatment for sickle cell disease

Tessera Therapeutics, a biotech developing a new approach to genome engineering, has entered into an agreement with the Bill & Melinda Gates Foundation to jointly fund the company’s in vivo programme for sickle cell disease (SCD). The funding includes an initial investment, with potential total investment of up to $50… Read More

#News